Irinotecan-induced dysarthria: an insight into its pathogenesis?
作者信息
Gomez Jesus A, Sanchez Ines, Ramirez Jose A
机构信息
Center for Integrative Cancer Medicine, Sierra Medical Center, El Paso, Texas.
出版信息
Gastrointest Cancer Res. 2008 Jul;2(4):209-10.
Abstract
摘要
相似文献
1
Irinotecan-induced dysarthria: an insight into its pathogenesis?伊立替康引起的构音障碍：对其发病机制的见解？
Gastrointest Cancer Res. 2008 Jul;2(4):209-10.
2
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review.伊立替康诱发的短暂性构音障碍：病例系列及文献综述更新
Oncol Ther. 2020 Jun;8(1):147-160. doi: 10.1007/s40487-019-00106-z. Epub 2020 Jan 6.
3
Dysarthria induced by irinotecan in a patient with colorectal cancer.结直肠癌患者因伊立替康导致的构音障碍。
Am J Health Syst Pharm. 2013 Jul 1;70(13):1140-3. doi: 10.2146/ajhp120542.
4
[A case of sigmoid colon cancer with temporary dysarthria associated with irinotecan].[1例与伊立替康相关的伴有暂时性构音障碍的乙状结肠癌]
Gan To Kagaku Ryoho. 2011 Aug;38(8):1375-7.
5
Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies.伊立替康相关的构音障碍：一项单机构病例系列研究及其对胃肠道恶性肿瘤患者的管理启示
J Oncol Pharm Pract. 2019 Jun;25(4):980-986. doi: 10.1177/1078155218763044. Epub 2018 Mar 21.
6
Irinotecan-induced dysarthria: A case report and review of the literature.伊立替康所致构音障碍：一例病例报告及文献综述
J Oncol Pharm Pract. 2017 Apr;23(3):226-230. doi: 10.1177/1078155216634181. Epub 2016 Jul 8.
7
[Dysarthria during irinotecan administration].
Rev Med Interne. 2002 Nov;23(11):950-1. doi: 10.1016/s0248-8663(02)00707-5.
8
Irinotecan-induced dysarthria.伊立替康引起的构音障碍。
J Natl Cancer Inst. 2001 Sep 19;93(18):1419-20. doi: 10.1093/jnci/93.18.1419.
9
Irinotecan chemotherapy associated with transient dysarthria and aphasia.
Ann Oncol. 2004 Jul;15(7):1147-8. doi: 10.1093/annonc/mdh277.
10
FOLFIRINOX-induced reversible dysarthria: A case report and review of previous cases.FOLFIRINOX方案诱导的可逆性构音障碍：一例病例报告及既往病例回顾
Oncol Lett. 2015 Oct;10(4):2662-2664. doi: 10.3892/ol.2015.3591. Epub 2015 Aug 11.
引用本文的文献
1
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review.伊立替康诱发的短暂性构音障碍：病例系列及文献综述更新
Oncol Ther. 2020 Jun;8(1):147-160. doi: 10.1007/s40487-019-00106-z. Epub 2020 Jan 6.
2
Irinotecan-Associated Dysarthria in Patients with Pancreatic Cancer: A Single Site Experience.胰腺癌患者伊立替康相关性构音障碍：单中心经验。
Am J Case Rep. 2020 Jun 28;21:e924058. doi: 10.12659/AJCR.924058.
3
FOLFIRINOX-induced reversible dysarthria: A case report and review of previous cases.FOLFIRINOX方案诱导的可逆性构音障碍：一例病例报告及既往病例回顾
Oncol Lett. 2015 Oct;10(4):2662-2664. doi: 10.3892/ol.2015.3591. Epub 2015 Aug 11.
4
Irinotecan-induced dysarthria.伊立替康引起的构音障碍。
Case Rep Oncol. 2012 Jan;5(1):47-51. doi: 10.1159/000336156. Epub 2012 Jan 18.
本文引用的文献
1
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.一项关于每两周使用伊立替康联合吉西他滨、5-氟尿嘧啶、亚叶酸钙和顺铂治疗转移性胰腺癌患者的I-II期研究的汇总疗效分析。
Anticancer Drugs. 2007 Mar;18(3):263-71. doi: 10.1097/CAD.0b013e3280121334.
2
Irinotecan chemotherapy associated with transient dysarthria and aphasia.
Ann Oncol. 2004 Jul;15(7):1147-8. doi: 10.1093/annonc/mdh277.
3
[Dysarthria during irinotecan administration].
Rev Med Interne. 2002 Nov;23(11):950-1. doi: 10.1016/s0248-8663(02)00707-5.
4
Irinotecan-induced dysarthria.伊立替康引起的构音障碍。
J Natl Cancer Inst. 2001 Sep 19;93(18):1419-20. doi: 10.1093/jnci/93.18.1419.
5
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).伊立替康（CPT-11）的临床药代动力学与代谢
Clin Cancer Res. 2001 Aug;7(8):2182-94.
6
Irinotecan in the treatment of colorectal cancer: clinical overview.伊立替康治疗结直肠癌：临床概述
J Clin Oncol. 2001 Mar 1;19(5):1501-18. doi: 10.1200/JCO.2001.19.5.1501.
7
Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan.一种解释抗癌药物伊立替康不良胆碱能效应的新机制的表征。
Br J Pharmacol. 2001 Jan;132(1):73-84. doi: 10.1038/sj.bjp.0703766.
8
Irinotecan-induced central nervous system toxicity: a case report.伊立替康所致中枢神经系统毒性：一例报告
J Natl Cancer Inst. 1999 Apr 7;91(7):647. doi: 10.1093/jnci/91.7.647.
9
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.晚期结直肠癌患者伊立替康所致迟发性腹泻的病理生理学与治疗：一项前瞻性评估
J Clin Oncol. 1998 Aug;16(8):2745-51. doi: 10.1200/JCO.1998.16.8.2745.
10
Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.9-氨基喜树碱（9-AC）、伊立替康（CPT-11）和SN-38在非人灵长类动物中的血浆和脑脊液药代动力学
Cancer Chemother Pharmacol. 1998;41(6):464-8. doi: 10.1007/s002800050768.
Zotero 插件